{"id":"agn-229666","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RXR agonists activate retinoid X receptors, which are nuclear receptors involved in regulating inflammatory pathways and cellular differentiation. By selectively targeting RXR, AGN-229666 aims to suppress inflammatory responses while promoting healing, particularly in ocular and dermatological conditions. This mechanism allows modulation of immune and epithelial cell function without the systemic effects associated with broader retinoid signaling.","oneSentence":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:19.047Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Meibomian gland dysfunction"}]},"trialDetails":[{"nctId":"NCT02161146","phase":"PHASE3","title":"AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-04","conditions":"Conjunctivitis, Allergic","enrollment":240},{"nctId":"NCT02082262","phase":"PHASE3","title":"AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-03","conditions":"Conjunctivitis, Allergic","enrollment":140},{"nctId":"NCT01754766","phase":"PHASE2","title":"AGN-229666 for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-10","conditions":"Allergic Conjunctivitis","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AGN-229666","genericName":"AGN-229666","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair. Used for Dry eye disease, Meibomian gland dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}